NASDAQ:ORGS Orgenesis (ORGS) Stock Price, News & Analysis $1.30 -0.10 (-7.14%) (As of 12/20/2024 04:04 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSustainabilityTrends About Orgenesis Stock (NASDAQ:ORGS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Orgenesis alerts:Sign Up Key Stats Today's Range$1.29▼$1.4050-Day Range$0.89▼$3.3952-Week Range$0.87▼$10.80Volume2,827 shsAverage Volume21,911 shsMarket Capitalization$6.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Read More… Receive ORGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter. Email Address ORGS Stock News HeadlinesAnalyzing Zentalis Pharmaceuticals (NASDAQ:ZNTL) & Orgenesis (NASDAQ:ORGS)December 19 at 3:27 AM | americanbankingnews.comComparing BridgeBio Pharma (NASDAQ:BBIO) and Orgenesis (NASDAQ:ORGS)December 18, 2024 | americanbankingnews.com$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.December 22, 2024 | Stansberry Research (Ad)Orgenesis Inc. Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comOrgenesis Provides Third Quarter 2024 Business UpdateNovember 13, 2024 | markets.businessinsider.comOrgenesis Expands Board with Three New AppointmentsNovember 3, 2024 | markets.businessinsider.comOrgenesis commences trading on OTCQX Best MarketOctober 22, 2024 | markets.businessinsider.comOrgenesis Commences Trading on OTCQX® Best MarketOctober 21, 2024 | markets.businessinsider.comSee More Headlines ORGS Stock Analysis - Frequently Asked Questions How have ORGS shares performed this year? Orgenesis' stock was trading at $4.08 on January 1st, 2024. Since then, ORGS stock has decreased by 68.1% and is now trading at $1.30. View the best growth stocks for 2024 here. How were Orgenesis' earnings last quarter? Orgenesis Inc. (NASDAQ:ORGS) released its earnings results on Friday, August, 11th. The company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of $0.60 by $2.10. The business earned $6.98 million during the quarter. When did Orgenesis' stock split? Orgenesis shares reverse split before market open on Wednesday, September 25th 2024. The 1-10 reverse split was announced on Monday, September 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Does Orgenesis have any subsidiaries? Orgenesis subsidiaries include Koligo Therapeutics, and Tamir Biotechnology Inc. How do I buy shares of Orgenesis? Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Orgenesis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Orgenesis investors own include NVIDIA (NVDA), Energy Transfer (ET), BioLineRx (BLRX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and Enbridge (ENB). Company Calendar Last Earnings8/11/2023Today12/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORGS CUSIPN/A CIK1460602 Webwww.orgenesis.com Phone(480) 659-6404FaxN/AEmployees150Year Founded2008Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,360,000.00 Net Margins-3,827.81% Pretax Margin-3,931.93% Return on EquityN/A Return on Assets-130.18% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$662,000.00 Price / Sales9.42 Cash FlowN/A Price / Cash FlowN/A Book Value($6.58) per share Price / Book-0.20Miscellaneous Outstanding Shares4,799,000Free Float4,527,000Market Cap$6.24 million OptionableOptionable Beta1.31 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ORGS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.